Sanders-Klobuchar Shred GOP Cruelty In Debate Against Graham-Cassidy

The debate came shortly after Susan Collins announced her opposition to the Graham-Cassidy bill, a blow to the GOP’s Obamacare repeal efforts that may ultimately prove to be fatal.

Sen. Bill Cassidy, R-La., center, listens as Sen. Lindsey Graham, R-S.C., left, speaks, accompanied by Senate Majority Leader Mitch McConnell of Ky., on Capitol Hill, Tuesday, Sept. 19, 2017 in Washington. (AP/Alex Brandon)

Shortly following Sen. Susan Collins' (R-Maine) announcement that she plans to vote against the latest iteration of Trumpcare—likely dealing a death blow to deeply unpopular legislation that was already teetering on the edge of collapse—Sens. Bernie Sanders (I-Vt.) and Amy Klobuchar (D-Minn.) piled it on the GOP Monday night in a CNN-hosted debate


Ethanol Proponents Accuse Oil Industry Of Forcing Out The Competition

Senators demand feds investigate allegations that gas station owners are being strong-armed by oil companies.

In this Feb. 13, 2012 photo, a gas station attendant pumps gas, in Portland, Ore. At an average of $3.51 a gallon, gas is up 23 percent since Jan. 1. And experts say motorists could pay a record $4.25 a gallon by late April. (AP Photo/Rick Bowmer)

Two senators from farmland states are calling on the Federal Trade Commission to investigate allegations that oil companies pressured gas stations to rig the system to bump ethanol fuel out of the picture. The allegations claim oil companies targeted independent gas stations, convincing them to allow oil companies to work around federal standards


Bipartisan Bill Targets Drug Company Pay-Offs That Inflate Price Of Medication

Some brand-name drug makers have paid their generic competitors to delay the introduction of cheaper drugs.

Anti-depressant drugs produced by Eli Lilly are shown here. (AP Photo/Darron Cummings, file)

Consumers have been kept in the dark about a secret deal between brand-name pharmaceutical companies and their generic competition. Since 2005, some brand-name drug makers have paid their generic competitors to delay the introduction of cheaper drugs, extending their monopoly and forcing consumers to pay higher prices for life-saving